B. Riley Securities Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $31
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
B. Riley Securities analyst Madison El-Saadi maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $26 to $31.
B. Riley Securities analyst Madison El-Saadi maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $26 to $31.